Novomix 30 100 U/ml Suspension for Injection
PDF Leaflet Revision Date: 12 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
For treatment of insulin requiring patients with diabetes mellitus.
Dosage (summary)
Individualized; starting dose for Type 2 diabetes is 6 U at breakfast and dinner.
Onset of Action / Duration
Onset: 10-20 mins, Duration: up to 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Paediatric population (10+ years)
Pregnancy & Breastfeeding
Insulin requirements may change during pregnancy; safe during breastfeeding.
Key Drug Interactions
- Oral hypoglycaemic agents
- Beta-blockers
- Alcohol
Contraindications
- Hypoglycaemia
- Hypersensitivity to insulin aspart
- Intravenous injection
Common side effects
- Hypoglycaemia
- Injection site reactions
- Lipodystrophy
Counselling Points
- Check insulin label before injection
- Rotate injection sites
- Carry sugar for hypoglycaemia
Serious warnings
- Risk of severe hypoglycaemia
- Do not use in insulin pumps
- Monitor for hyperglycaemia
Important Disclaimer
The Novomix 30 100 U/ml Suspension for Injection professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
